文献速递糖尿病

糖尿病技术:最新进展

Diabetes technology: an update.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

本文是一篇迷你综述,总结糖尿病技术的最新进展。持续葡萄糖监测(CGM)和自动胰岛素输注系统与1型和2型糖尿病患者糖化血红蛋白(HbA1c)显著改善、目标范围内时间(70-180 mg/dL)增加以及严重低血糖和糖尿病酮症酸中毒减少相关。CGM也被探索用于监测早期1型糖尿病进展,但全球在糖尿病技术和胰岛素可及性方面仍存在显著差异。

要点

  • CGM和自动胰岛素输注系统与HbA1c改善、目标范围内时间增加及严重低血糖和DKA减少相关。
  • 近期数据显示这些技术在1型糖尿病病程早期即可改善结局。
  • CGM正被探索用于监测早期1型糖尿病进展及预防3期起病时DKA。

核心结论

  • CGM和自动胰岛素输注系统与1型和2型糖尿病患者血糖管理改善相关。
  • 糖尿病技术和胰岛素可及性在全球仍存在显著差异,需促进公平可及。

研究设计与样本

  • 本文为迷你综述,总结近期发表的数据并强调新兴应用。

主要发现

  • CGM和自动胰岛素输注系统与1型和2型糖尿病患者HbA1c显著改善、目标范围内时间(70-180 mg/dL)增加相关。
  • 上述技术与严重低血糖和糖尿病酮症酸中毒减少相关。
  • 近期数据显示这些技术在1型糖尿病病程早期即可改善结局。
  • CGM正被探索用于监测从2抗体阳性早期1型糖尿病进展,以识别可能受益于疾病修饰治疗者。
  • CGM也被探索用于预防3期(需要胰岛素)1型糖尿病起病时的糖尿病酮症酸中毒。

关键数值与推荐

  • 目标范围内时间定义为70-180 mg/dL。

临床怎么用

  • CGM和自动胰岛素输注系统可用于改善1型和2型糖尿病患者的血糖管理。
  • CGM可考虑用于监测早期1型糖尿病进展并识别可能受益于疾病修饰治疗者。

局限性

  • 全球糖尿病技术和胰岛素可及性存在显著差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diabetes is one of the most prevalent chronic diseases worldwide, with rates that continue to increase. More than 30 years ago, the Diabetes Control and Complications Trial demonstrated that intensive glucose management decreased long-term vascular complications. Unfortunately, many people with diabetes still struggle to meet glycemic goals. In this mini-review, we highlight advances in diabetes technology that are associated with improvements in glycemic management. Continuous glucose monitoring (CGM) and automated insulin delivery systems are associated with significant improvements in glycated hemoglobin (HbA1c), time in range (70-180 mg/dL), and decreases in severe hypoglycemia and diabetic ketoacidosis in people with both type 1 and type 2 diabetes. Recent data show that these technologies improve outcomes early in the course of type 1 diabetes. CGM is also being explored as a tool to monitor progression through early-stage type 1 diabetes (2 antibodies positive) to identify individuals who may benefit from disease-modifying therapies as well as to prevent the onset of diabetic ketoacidosis at onset of stage 3 (insulin-requiring) type 1 diabetes. Adjunctive pharmacologic therapies and artificial intelligence may further expand and improve therapies, offering potential synergistic benefits. However, there continue to be significant disparities in access to diabetes technologies and access to insulin worldwide. This mini-review summarizes recently published data, highlights emerging applications, and underscores the need to pair technological innovation with strategies that promote equitable access and support for diabetes care to improve outcomes for all people with diabetes.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Prahalad P, Zaharieva D, Maahs DM, et al. Diabetes technology: an update. J Clin Endocrinol Metab. 2026. PMID: 41973910. doi:10.1210/clinem/dgag164

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。